FDA/CMS Parallel Review of Medical Products Limited Only by Sponsors' Reluctance, CMS Official Says | GenomeWeb

Originally published Dec. 5.

By Turna Ray

Although players in the drug and diagnostics industries have often extolled the benefits of simultaneous regulatory and reimbursement review for medical products, sponsors have so far shown resistance to such a model when provided with the opportunity, according to an official with the Centers for Medicare & Medicaid Services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.